By Marc Navarro Gonzalez 
 

Sanofi SA (SAN.FR) said Wednesday that a phase 3 trial evaluating its drug Dupixent to treat moderate to severe atopic dermatits in adolescents met its primary and key secondary endpoints.

The French drug maker said the trial showed treatment with Dupixent as monotherapy "significantly improved measure of overall disease severity, skin clearing, itching and certain health-related quality of life measures."

Patients treated with Dupixent had significant improvement in disease severity at 16 weeks, Sanofi said.

In 2016, the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents between 12 and 17 years old, and for the treatment of severe cases of the disease in children between six months and 11 years of age.

 

Write to Marc Navarro Gonzalez at marc.navarro@dowjones.com

 

(END) Dow Jones Newswires

May 16, 2018 01:48 ET (05:48 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Sanofi.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Sanofi.